SD BIOSENSOR announced on the 13th that it held a ceremony for the completion of its new factory in Gurugram, India.
The company plans to secure its global annual production capacity by more than 2.9 times through this new factory completion and strengthen its competitiveness in the in vitro diagnostics market. The new factory covers a total area of 54,116.48㎡ (16,398.9 pyeong), more than 7 times larger than the previous factory in India.
The new factory has introduced the latest automation equipment to enhance productivity and efficiency. A one-step production system that can handle all processes of production, quality control, and shipping within one building has also been implemented.
SD BIOSENSOR plans to begin production this month not only of its dedicated brand "ULTRA" but also of the global brand "STANDARD" rapid immunodiagnostics, fluorescent immunodiagnostics, enzyme immunodiagnostics, field molecular diagnostics, and blood glucose measurement products.
Six products that have received certification from the World Health Organization prequalification (WHO PQ) are also expected to be produced in India, which will expand procurement for global public health. The new factory in India is located in a strategic position that allows utilization of major ports and rail networks. This will reduce logistics costs and establish a faster and more economical global supply chain. With abundant labor, low labor costs, and the local procurement of raw materials in India, the manufacturing costs are expected to decrease, ensuring cost competitiveness and increasing margins.
The new factory in India is an eco-friendly facility equipped with an energy-saving facility. It has increased energy efficiency by minimizing electricity usage while recycling cooling water and gas.
Choi Young-sik, chairman of SD BIOSENSOR, said, "The completion of the new factory has further strengthened our responsiveness in the global market," adding, "Based on the excellent facilities and production capacity of the new factory, we will continue to provide innovative diagnostic solutions and contribute to the advancement of the global healthcare industry."